Trastuzumab pamirtecan represents a potentially practice-changing therapy in recurrent endometrial cancer, a space with few effective options. With Breakthrough Therapy designation and strong Phase 2 data across HER2 expression levels, the path toward BLA filing in 2026 enhances near-term catalyst potential. Traders should monitor upcoming regulatory interactions and Phase 3 readouts, particularly DYNASTY-Breast02 later this year.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $96.70entry
- T+1 · 7mo ago +1.77%α +0.56% · $98.41
- T+5 · 7mo ago +8.78%α +5.48% · $105.19
- T+20 · 6mo ago −3.47%α −11.20% · $93.34
- T+60 · 4mo ago −3.28%α −12.20% · $93.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in advanced endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival across all HER2 expression levels, with a manageable safety profile. The data support the drug's potential in a high-unmet-need population, including those with prior checkpoint inhibitor exposure.
Key Facts
- Phase 2 cohort of 145 patients with advanced HER2-expressing endometrial cancer met primary endpoint of objective response rate (ORR).
- Confirmed ORR was 47.9% in centrally tested patients (n=96), with 49.3% in those previously treated with checkpoint inhibitors.
- Median progression-free survival was 8.1 months (95% CI: 5.5, 11.8) in centrally tested patients.
- Trastuzumab pamirtecan showed activity across all HER2 expression levels (IHC1+, IHC2+, IHC3+) and in real-world populations including those with visceral metastases.
- Safety profile was manageable; grade ≥3 treatment-related adverse events occurred in 46.9% of patients, with 4.8% experiencing grade ≥3 ILD/pneumonitis.
- FDA has granted Fast Track and Breakthrough Therapy designations for this indication; BLA submission planned in 2026 pending regulatory feedback.
- Global Phase 3 trial (Fern-EC-01) is ongoing, with plans to file BLA subject to FDA input.
Financial Impact
High-value oncology pipeline advancement with registrational potential; could expand BNTX's market beyond mRNA into targeted cancer therapies.
Risk Factors
- Phase 2 data may not be replicated in larger Phase 3 trials.
- Safety signals, including 4.8% grade ≥3 ILD/pneumonitis, could impact regulatory or commercial acceptance.
- Dependence on successful collaboration with DualityBio for development and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272109 |
Track record
38 reports on BNTX
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers